Prevention, recognition, and management of adverse events associated with gemtuzumab ozogamicin use in acute myeloid leukemia

Gemtuzumab ozogamicin (GO), a humanized anti-CD33 monoclonal antibody conjugated to the cytotoxic antibiotic agent calicheamicin, is approved for the treatment of newly-diagnosed CD33 + AML in adults and children ≥ 1 month old, and relapsed or refractory CD33 + AML in adults and children ≥ 2 years o...

Descripción completa

Detalles Bibliográficos
Autores principales: Cortes, Jorge E., de Lima, Marcos, Dombret, Hervé, Estey, Elihu H., Giralt, Sergio A., Montesinos, Pau, Röllig, Christoph, Venditti, Adriano, Wang, Eunice S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7559451/
https://www.ncbi.nlm.nih.gov/pubmed/33059764
http://dx.doi.org/10.1186/s13045-020-00975-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7559451/
https://www.ncbi.nlm.nih.gov/pubmed/33059764
http://dx.doi.org/10.1186/s13045-020-00975-2

Ejemplares similares